Audicin Raises $1.9M for Neurotech Nervous System Tools

Helsinki-based neurotechnology innovator Audicin has successfully closed a $1.9 million funding round, injecting crucial capital into its mission to develop advanced tools for real-time nervous system regulation. This significant investment, a blend of private capital and a grant from Business Finland's Deep Tech Accelerator programme, will accelerate the commercialization of its unique auditory-based solutions.

The funding round saw continued support from prominent figures in the Finnish tech scene, including follow-on investment from Petteri Lahtela and Virpi Tuomivaara. These individuals are recognized for their foundational roles at Oura Health, the pioneering smart ring company, underscoring their belief in Audicin's disruptive potential within the digital health and wellness sectors.

Founded in 2022 by an all-female leadership team comprising CEO Laura Avonius, Victoria Williamson, and Mariana Sousa Aguiar, Audicin leverages sophisticated brainwave entrainment and auditory engineering techniques. Their core technology generates background audio sessions designed to guide users into desired physiological states, such as enhanced focus, accelerated stress recovery, or improved sleep quality, all without demanding active user participation. This passive approach differentiates Audicin in a market increasingly focused on user-friendly, integrated wellness solutions.

Audicin's product suite is designed for broad applicability. It includes adaptive audio sessions that respond to physiological cues, time of day, or in-app triggers. Furthermore, the company offers an Audicin for Apps SDK, enabling seamless integration with third-party digital health platforms and consumer applications. A key development in progress is a Sleep Headband, engineered for offline functionality in environments where connectivity is limited, such as healthcare facilities and defense installations. The technology is already compatible with leading wearables like Oura, Apple Watch, Garmin, and Whoop, facilitating a data-driven approach to nervous system management.

The newly acquired funds are earmarked for strategic growth initiatives. Key priorities include scaling the commercial rollout of the mobile application, advancing the Sleep Headband to market, and expanding the reach of the SDK. Significant investment will also be directed towards ongoing research and development, ensuring Audicin remains at the forefront of neurotechnology innovation. The company has already reported promising early commercial engagement across the defense, high-performance, and general wellness markets, indicating strong market receptivity.

This latest funding brings Audicin's total capital raised to approximately $3 million, following a €520,000 pre-seed round secured earlier in 2024. The company's progress highlights the growing investor interest in technologies that offer non-invasive, data-backed solutions for mental well-being and cognitive performance. As the digital therapeutics and personalized wellness markets continue their rapid expansion, projected to reach hundreds of billions globally in the coming years, Audicin is strategically positioned to capture a significant share by addressing fundamental human needs for stress management and optimized cognitive function.